J.W. Cole Advisors, Inc. Esperion Therapeutics, Inc. Transaction History
J.W. Cole Advisors, Inc.
- $2.42 Billion
- Q4 2024
A detailed history of J.W. Cole Advisors, Inc. transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, J.W. Cole Advisors, Inc. holds 30,200 shares of ESPR stock, worth $47,716. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,200Holding current value
$47,716% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ESPR
# of Institutions
215Shares Held
129MCall Options Held
1.78MPut Options Held
1.27M-
Wasatch Advisors Inc Salt Lake City, UT24.5MShares$38.7 Million0.27% of portfolio
-
Black Rock Inc. New York, NY14MShares$22.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$18.5 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$15.7 Million0.44% of portfolio
-
Morgan Stanley New York, NY6.31MShares$9.97 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $105M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...